Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir by Brown, Patrick R et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Internal Medicine Articles Internal Medicine 
10-1-2018 
Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C 
Virus Treatment With Ledipasvir/Sofosbuvir. 
Patrick R. Brown 
Henry Ford Health System 
Omar Sadiq 
Henry Ford Health System, OSADIQ1@hfhs.org 
Alexander Weick 
Henry Ford Health System 
Adrienne Lenhart 
Henry Ford Health System 
Mohammad Elbatta 
Henry Ford Health System 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/internalmedicine_articles 
Recommended Citation 
Brown PR, Sadiq O, Weick A, Lenhart A, Elbatta M, Fernandez C, Kutait A, Pompa R, and Jafri SM. Acute 
kidney injury in patients undergoing chronic hepatitis c virus treatment with ledipasvir/sofosbuvir. Hepatol 
Commun 2018; 2(10):1172-1178. 
This Article is brought to you for free and open access by the Internal Medicine at Henry Ford Health System 
Scholarly Commons. It has been accepted for inclusion in Internal Medicine Articles by an authorized administrator 
of Henry Ford Health System Scholarly Commons. 
Authors 
Patrick R. Brown, Omar Sadiq, Alexander Weick, Adrienne Lenhart, Mohammad Elbatta, Christopher 
Fernandez, Anas Kutait, Robert Pompa, and Syed-Mohammed Jafri 
This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
internalmedicine_articles/24 
1172
Hepatology CommuniCations, Vol. 2, no. 10, 2018  
Acute Kidney Injury in Patients 
Undergoing Chronic Hepatitis C Virus 
Treatment With Ledipasvir/Sofosbuvir
Patrick R. Brown,1 Omar Sadiq,1 Alexander Weick,2 Adrienne Lenhart,1 Mohammad Elbatta,2 Christopher Fernandez,2  
Anas Kutait,2 Robert Pompa,2 and Syed-Mohammed Jafri2
Ledipasvir-sofosbuvir, a once-a-day, oral combination pill, was approved in 2014 for the treatment of chronic hepatitis C 
infection. Initial trials did not comment on nephrotoxicity; however, recent data suggest a risk of acute kidney injury (AKI) 
with the use of the medication. We assessed the rates of AKI in patients undergoing ledipasvir-sofosbuvir in a large, urban 
tertiary care center. This single-center retrospective observation study included all patients undergoing therapy from 
October 1, 2014, to October 1, 2015. Rates of AKI, defined by more than a 0.3 mg/dL increase in serum creatinine level, 
were calculated. Patients were followed 12 weeks after therapy to assess for sustained viral response as well as to assess for 
improvement of AKI after completion of therapy, defined by less than 0.2 mg/dL above baseline serum creatinine. In total, 
197 patients were included in the final analysis who had completed ledipasvir-sofosbuvir therapy and completed laboratory 
values. Among the patients treated, 38 (19%) had AKI during therapy. An additional 4 (2%) had AKI at the end of therapy. 
Of the 38 patients who experienced AKI, 20 (53%) had improvement in serum creatinine to less than 0.2 mg/dL above their 
baseline. When comparing for chronic kidney disease (CKD) stage, those with CKD I or II experienced AKI 17% of the 
time compared with 47% of the time in CKD III or worse (P = 0.005). Conclusion: AKI was seen in nearly one-fifth of our 
patients, and patients with CKD stage III or worse are at increased risk. Although ledipasvir-sofosbuvir is generally safe in 
the general population, close monitoring of renal function is recommended. (Hepatology Communications 2018;2:1172-1178).
Hepatitis C virus (HCV) has an estimated global prevalence of 2%-3% with 130-170 million people infected with HCV.(1) HCV 
causes chronic inflammation of the liver leading 
to chronic hepatitis, which can advance to liver cir-
rhosis and hepatocellular carcinoma and significant 
extrahepatic complications.(2) Additionally, HCV has 
been shown to have a significant negative effect on 
a patient’s overall quality of life, including decreased 
work hours and productivity and increased health 
care costs.(3) Cirrhosis and hepatocellular carcinoma 
related to HCV infection represent the most common.
indications for liver transplantation in the United 
States due to poor treatment options.(4)
Until recently, interferon-based treatments were the 
backbone of HCV treatment options.(5) Unfortunately, 
therapy was only modestly effective and associated 
with significant side effects.(6) Therefore, research has 
focused on HCV eradication using oral antiviral ther-
apy. Recent clinical studies have demonstrated efficacy 
using the nucleotide analogue inhibitor sofosbuvir 
(Sovaldi; Gilead Sciences, Inc., Foster City, CA) as the 
backbone in treatment of nontransplant and posttrans-
plant recurrent HCV.(7) Both the ION-1 and ION-2 
Abbreviations: AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; 
HCV, hepatitis C virus; LDV/SOF, ledipasvir/sofosbuvir; SVR, sustained virologic response.
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trials demonstrated nearly 99% efficacy in the treat-
ment of nontransplant, noncirrhotic HCV patients 
using sofosbuvir in a fixed-dose combination with the 
NS5A inhibitor ledipasvir (Harvoni, Gilead Sciences, 
Inc.), both with and without ribavirin.(8,9) The side 
effect profile of ledipasvir/sofosbuvir (LDV/SOF) has 
been relatively mild and the drug has been well toler-
ated in trials, especially compared with previous inter-
feron-based regimens.
The ION trials report that LDV/SOF therapy 
was primarily complicated by headaches or fatigue in 
approximately 10% of patients. Less frequently, patients 
experienced rashes, nausea, diarrhea, and insomnia. 
Serious side effects, such as nephrotoxicity, were not 
demonstrated by the ION-1 and ION-2 trials; how-
ever, these trials were conducted in a controlled clinical 
setting with rigorous exclusion criteria. Such trials are 
not always entirely reflective of the general patient pop-
ulation. Early data suggest possible risk of renal impair-
ment during treatment with the use of LDV/SOF.(11) 
LDV/SOF is mostly cleared renally,(10) and given this, 
we studied the renal safety and rates of acute kidney 
injury (AKI) in patients with chronic HCV undergo-
ing LDV/SOF direct acting antiviral therapy.
Methods
This single-center cohort retrospective observational 
study included all consecutive patients without history 
of liver transplants who initiated HCV treatment on 
LDV/SOF from October 1, 2014, to October 1, 2015. 
Patients were treated at Henry Ford Health Hospital 
in Detroit, Michigan, an urban, tertiary care center. 
All included patients completed 8, 12, 16, or 24 weeks 
of therapy with or without ribavirin and had available 
creatinine values before, during, and after therapy. All 
charts were reviewed by the authors. The institutional 
review board approved the study.
Background information including age, gender, race, 
BMI, degree of fibrosis or cirrhosis, HCV genotype, 
prior HCV treatment history, and date of treatments 
were collected. Baseline laboratory characteristics 
before treatment initiation included hemoglobin, white 
blood cell count, platelets, creatinine, international 
normalized ratio, aspartate aminotransferase, alanine 
aminotransferase, albumin, and total bilirubin. Patients 
were evaluated for hemoglobin nadir, peak creatinine 
while on treatment, as well as any adverse effects expe-
rienced while on therapy. All patients underwent rou-
tine lab draw at least every 4 weeks during treatment. 
More frequent lab draws were at the discretion of the 
prescribing clinician. Patients received courtesy calls if 
lab draws were missed. Posttreatment laboratory anal-
ysis included hemoglobin, creatinine, total bilirubin, 
aspartate aminotransferase, and alanine aminotrans-
ferase. All patients underwent posttreatment lab draws 
at 4, 12, and 24 weeks. HCV viral load was recorded 
prior to treatment initiation, at 4 and 12 weeks on 
treatment, at the end of treatment, and finally 4 and 
12 weeks posttreatment to determine sustained viro-
logic response (SVR12). An undetectable viral load on 
HCV RNA 12 weeks after completion of LDV/SOF 
was considered an SVR.
The primary endpoint of this study was the occur-
rence of AKI during antiviral therapy, defined as an 
increase of at least 0.3 mg/dL or at least 50% in serum 
creatinine level when compared with baseline values 
or more than a 25% reduction in estimated glomerular 
filtration rate (eGFR) when compared with baseline 
eGFR. eGFR was calculated using the abbreviated 
Modification of Diet in Renal Disease equation: 
eGFR (mL/min/1.73 m2) = 186 × (creatinine (mg/
dL) ÷ 88.4) − 1.154 × (age)0.203 × (0.742 if female) × 
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(1.210 if African American). The primary endpoint 
was considered reached if any single lab measurement 
was recorded above these thresholds. Clinically signif-
icant renal impairment was considered when patients 
reached the primary endpoint and had more than 50% 
reduction in eGFR. Normalization of renal function 
was considered if follow-up creatinine was no more 
than 0.2 mg/dL from baseline or eGFR was less than 
or equal to 25% of baseline eGFR. Each patient expe-
riencing AKI was reviewed for urinalysis and/or renal 
biopsy to assess the mechanism of injury and/or alter-
native etiology of intertreatment renal injury.
Chronic kidney disease (CKD) was defined using 
the Kidney Disease Improving Global Outcomes 
definition. CKD stage I is defined as GFR ≥ 90 (mL/
min/1.73 m2), CKD stage II is defined as GFR ≥ 60 ≤ 
89 (mL/min/1.73 m2), CKD stage III is defined as GFR 
≥ 30 ≤ 59 (mL/min/1.73 m2), CKD stage IV is defined 
as GFR ≥ 15 ≤ 29 (mL/min/1.73 m2), and CKD stage 
V is defined as GFR ≤ 15 (mL/min/1.73 m2).
Clinical data were compiled from the electronic med-
ical record system. The data collected were expressed as 
means with SDs, medians with ranges, or as frequen-
cies (percentages). For comparisons of CKD stages, a 
Student t test was used. Multivariable logistic regression 
analyses were used to assess factors associated with AKI. 
Clinical factors available that were deemed important 
and included in the analysis included age, race, sex, body 
mass index (BMI), CKD stage, cirrhosis history, HCV 
genotype, pretreatment hemoglobin, pretreatment 
white blood cell count, pretreatment serum albumin, 
and pretreatment serum total bilirubin. A P < 0.05 was 
considered statistically significant. Results are presented 
with an OR and 95% confidence intervals (CIs).
Results
A total of 306 charts of HCV-infected patients 
undergoing LDV/SOF treatment were initially 
reviewed. Of these, 105 had not completed therapy or 
did not have complete serum creatinine levels, 1 patient 
had end-stage renal disease and was on hemodialysis, 
and 3 patients died during treatment. These patients 
did not undergo further analysis.
A total of 197 patients were included in the final 
analysis. Table 1 depicts patient baseline demographics. 
The cohort consisted of 90 African Americans (45%), 
78 Caucasians (40%), and 29 other or unspecified races 
(15%). Participants were predominantly male (59%) 
with a mean age of 60.8 years, who were also obese with a 
mean BMI of 28.1 kg/m2. All patients were treated with 
LDV/SOF-based treatment. One hundred nine (55%) 
taBle 1. Baseline CHaraCteristiCs
Variable Total (n = 197)
Age, years 60.7 ( 9.3)
Male 117 (59%)
BMI 28.1 ( 4.7)
Race
Caucasian 78 (40%)










Treatment experience 88 (45%)
Treatment duration
8 weeks 14 (7%)
12 weeks 133 (67%)
16 weeks 1 (0.5%)






Note: Data are presented as n (%) or means ( SDs).
taBle 2. Baseline CHaraCteristiCs oF 
treatment Failures













Note: Data are presented as n (%).
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patients were treatment naïve; 125 patients (63%) did 
not have evidence of cirrhosis; 14 patients (7%) under-
went 8 weeks, 133 patients (67%) underwent 12 weeks, 
1 patient (0.5%) underwent 16 weeks, and 49 patients 
(25%) underwent 24 weeks of treatment. Most patients 
were genotype 1 (95%); the remaining were genotype 
2 (3%) and genotype 3 (2%). Of the patients treated, 
63 (32%) were CKD stage II, 14 (7%) were CKD stage 
III, and 1 (0.5%) was CKD stage IV; the remaining 119 
patients (60%) were CKD stage I.
All patients undergoing treatment achieved SVR 
at the end of treatment, of which 186 (94%) obtained 
SVR12 and were considered cured. There were 11 treat-
ment failures, and baseline characteristics are found in 
Table 2. Of these failures, 7 (64%) were treatment naïve, 
8 (73%) were female, 8 (73%) were cirrhotic, and 10 
(91%) were genotype 1 with the remaining failure (1 
patient) being genotype 2. With regard to renal func-
tion, 7 (64%) failures were CKD stage I, and 2 (18%) 
failures each were CKD II and III, respectively.
taBle 3. patients eXperienCing aKD During lDV/soF tHerapy






Improvement of AKI SVR12
1 M 61 1B No 2.98 4.74 1.76 No Yes
2 M 44 1B Yes 1.78 2.80 1.02 No Yes
3 F 76 1B Yes 1.17 1.51 0.34 Yes Yes
4 M 64 1A No 1.56 2.03 0.47 Yes Yes
5 M 68 1B No 1.5 2.01 0.51 Yes Yes
6 F 69 1A Yes 1.15 1.67 0.52 Yes Yes
7 M 69 1A No 1.1 1.5 0.4 No Yes
8 M 64 1A Yes 1.05 1.53 0.48 No Yes
9 F 65 1B No 0.92 1.44 0.52 Yes Yes
10 F 48 1B No 0.77 1.28 0.51 Yes Yes
11 M 65 1A Yes 1.11 1.92 0.81 No Yes
12 F 66 1B No 0.85 1.33 0.58 Yes Yes
13 F 67 1A No 0.78 1.15 0.37 Yes Yes
14 M 64 1A No 0.98 2.34 1.36 No Yes
15 F 92 1B Yes 0.6 0.92 0.32 No Yes
16 M 61 1A No 0.94 1.27 0.33 Yes Yes
17 F 63 1A No 0.59 1.13 0.54 Yes Yes
18 F 56 1A Yes 0.7 1.15 0.45 No Yes
19 M 64 1B No 0.88 1.33 0.45 No Yes
20 F 77 1A Yes 0.55 1.17 0.62 Yes Yes
21 M 68 1A Yes 0.82 2.03 1.21 Yes Yes
22 M 65 1A Yes 0.65 0.96 0.31 Yes Yes
23 M 66 1B Yes 0.76 1.06 0.3 Yes Yes
24 M 47 3A No 0.65 0.95 0.3 Yes Yes
25 M 61 1A No 0.62 0.95 0.33 Yes Yes
26 M 59 1A Yes 0.60 1.02 0.42 No Yes
27 M 56 1A No 0.70 1.43 0.73 No Yes
28 M 61 1B Yes 0.68 1.19 0.51 Yes Yes
29 M 27 1A No 0.66 1.00 0.34 Yes Yes
30 M 57 1A No 0.56 0.91 0.35 Yes Yes
31 M 72 1B Yes 0.52 0.84 0.32 No Yes
32 M 41 2 Yes 0.57 0.9 0.33 No Yes
33 M 60 1B Yes 0.49 1.0 0.51 No Yes
34 M 60 1A Yes 0.55 0.85 0.30 No Yes
35 M 65 1A No 0.46 0.78 0.32 Yes Yes
36 M 73 1B No 1.11 1.83 0.72 No No
37 M 71 1A No 1.43 1.8 0.37 Yes No
38 M 64 1A Yes 0.8 1.26 0.46 No No
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Of the 197 patients, 38 (19%) were diagnosed with 
AKI by a rise in creatinine of at least 0.3 mg/dL during 
treatment, as provided in Table 3. Four (11%) of the 
patients had AKI workup, all (100%) had bland urine 
sediment. No patients underwent further AKI workup 
with renal biopsy. An additional 4 patients (2%) had 
AKI at the end of treatment, for a total of 42 patients 
experiencing AKI during or at the completion of treat-
ment. The mean creatinine levels before, during, and 
after antiviral treatment are shown in Fig. 1 for both 
the non-AKI cohort and the AKI cohort. Eighteen 
(25%) cirrhotic patients experienced AKI compared 
with 20 (16%) patients with no cirrhosis (P = 0.124). 
Of the 38 patients to experience AKI during treat-
ment, 20 (53%) recovered and 18 (47%) had not recov-
ered to less than 0.2 mg/dL serum creatinine greater 
than baseline at posttreatment week 12. Among the 38 
who experienced intratreatment AKI, 6 (16%) of the 
patients had an eGFR reduction greater than 50% and 
were considered clinically significant for this study.
Of the 18 patients who did not recover to within 
0.2 mg/dL of their pretreatment serum creatinine by 
posttreatment week 12, 6 (33%) recovered within 6 
months of treatment. The remaining 12 (66%) had 
ongoing renal function loss at 6 months following 
treatment. Additionally, 16 (89%) patients who did not 
recover by posttreatment week 12 achieved SVR12. Of 
the remaining 2 who did not achieve SV12R (11%), 1 
patient experienced renal recovery while the other did 
not.
An additional 64 (33%) had an eGFR reduction 
greater than 25% from baseline, of which 6 of 64 (9%) 
had more than a 50% reduction. At the end of treat-
ment, 11 additional patients (6%) demonstrated more 
than a 25% reduction from baseline eGFR. Of the 64 
who experienced reduced eGFR, 35 (55%) recovered to 
less than 25% from baseline eGFR. Of the 6 patients 
who experienced more than a 50% eGFR reduction, 
none completed treatment with a sustained reduction 
of more than 50%, 5 (83%) improved to less than 50% 
but more than 25% reduction, and 1 (17%) recovered 
to less than a 25% reduction.
With regard to preexisting renal impairment, 182 
patients (93%) were CKD II or better defined by eGFR 
being 60 mL/min/min2 or more, and 15 patients (7%) 
were CKD III or greater defined by eGFR being 60 
mL/min/min2 or less. Of the 15 patients with CKD 
III or greater, 7 (47%) were caused by hypertension, 4 
(27%) were caused by diabetes, 2 (17%) were caused by 
both hypertension and diabetes, and 1 (7%) was caused 
by interstitial nephritis and hepatorenal syndrome type 
II, each.
taBle 4. logistiC regression analysis For 
renal impairment
Variable Multivariable P Value
Age 1.08 (1.02-1.15) 0.015
Race 0.79 (0.30-2.10) 0.636
Sex 2.23 (1.19- 9.26) 0.022
BMI 0.96 (0.88-1.05) 0.390
CKD stage 8.19 (1.80-37.32) 0.007
Cirrhosis 1.56 (0.61-4.01) 0.353
HCV genotype 0.15 (0.02-1.30) 0.085
Pretreatment hemoglobin 0.95 (0.70-1.30) 0.736
Pretreatment white blood 
cell count
0.91 (0.73-1.13) 0.387
Pretreatment serum albumin 1.10 (0.43-2.84) 0.844
Pretreatment serum total 
bilirubin
1.50 (0.88-2.55) 0.138
Fig. 1. Dynamics of creatinine for patients undergoing 
ledipasvir/sofosbuvir. (A) Mean creatinine level (and standard 
error) at baseline, at maximum intertreatment, and at end of 
treatment for those who did not experience acute kidney injury 
during treatment. (B) Mean creatinine level (and standard error) 
at baseline, at maximum intertreatment, and at end of treatment 
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Thirty-one patients (17%) with CKD I (23 patients; 
19%) or II (8 patients; 13%) experienced AKI compared 
with 7 patients (47%) with CKD III (6 patients; 43%) or 
IV (1 patient; 100%) (P = 0.005) during treatment. An 
additional 3 patients with CKD I or II and 1 with CKD 
III or IV experienced AKI at the end of treatment. Of 
the 31 CKD I or II experiencing AKI during treatment, 
18 patients (58%) had renal recovery compared with 6 
patients (86%) with CKD III or IV (P = 0.227).
Multivariable logistic regression analysis showed that 
CKD III or greater (OR: 8.19, 95% CI: 1.8-37.3, P = 0.007), 
male gender (OR: 3.32, 95% CI: 1.19-9.26, P = 0.022), and 
age (OR: 1.08, 95% CI: 1.02-1.15, P = 0.015) were signifi-
cant predictors of AKI (Table 4).
Of the patients with preexisting CKD stage III or 
greater defined by eGFR being less than or equal to 
60 mL/min/min2, 13 of 15 (87%) patients achieved 
SVR12. Of the 7 intratreatment renal injuries, 5 (71%) 
patients improved to less than a 0.2 mg/dL increase 
from baseline serum creatinine.
Discussion
This study assessed the rates of renal impairment in 
patients undergoing HCV direct acting antiviral ther-
apy with LDV/SOF in a diverse, urban practice. The 
ION trials demonstrated that LDV/SOF was well tol-
erated renally in a controlled clinical setting. Since its 
introduction, LDV/SOF has been extremely well tol-
erated in healthy populations. Patients with normal or 
minimal CKD have not demonstrated a reliable effect 
on renal function in clinical trials, and documented 
adverse effects have been limited to nonspecific com-
plaints, such as fatigue, nausea, vomiting, and headaches.
Currently, there are limited published data suggest-
ing the risk of AKI during oral direct acting antiviral 
treatment.(11-13) These case reports and retrospective 
studies suggest an intrinsic cause of renal injury, with 
most of the available biopsies showing acute tubular 
necrosis (ATN) and acute interstitial nephritis (AIN). 
Most of these patients had returned to baseline renal 
function on cessation of LDV/SOF combination ther-
apy. It is speculated that our population experienced 
either ATN or AIN, similarly to previous studies, as 
their mechanism of injury.
Our experience was largely consistent with this, as we 
found that a notable percentage of patients experienced 
a transient increase in creatinine during therapy, which 
could occasionally lead to a more than 50% decrease 
in patients’ eGFR. Patients with CKD III or worse 
were found to be significantly more at risk compared 
with those with CKD I or II. Although most patients 
demonstrated normalization of serum creatinine back 
to pretreatment baseline, a small cohort of patients had 
a persistent decrease in eGFR. These findings are cer-
tainly concerning and warrant further investigation and 
longer posttreatment follow-up to assess renal function, 
especially in patients who have prior renal insufficiency.
Previous studies have shown that co-use of nonsteroi-
dal anti-inflammatory drugs (NSAIDs) and recurrent 
ascites were at increased risk for AKI during sofosbu-
vir-based antiviral therapy.(12) Additionally, patients 
with cirrhosis are at increased risk from AKI from com-
mon etiologies such as hypovolemia, sepsis, and hepato-
renal syndrome (HRS).(14) Although our study showed 
no significant difference in AKI occurrence between cir-
rhotic versus noncirrhotic, we did observe a 9% absolute 
risk reduction. We admit that our study does not adjust 
for all confounders that may have contributed to AKI 
beyond LDV/SOF use, including preexisting hyperten-
sion or diabetes, co-use of NSAIDs, known ascites, and 
development of HRS. Although our study does adjust 
for available potential confounders, these additional 
factors either predispose patients to AKI or are known 
etiologies of AKI,(12,14) and not having them available 
for analysis is a limitation of our study. Further investi-
gation should attempt to account for these factors.
Only 11% of our patients underwent further investi-
gations for other causes of renal injury with urinalysis, 
and no patients underwent renal biopsy to assess acute 
parenchymal changes, which is an additional limita-
tion for our study as we are unable to rule out other 
etiologies.
In our experiences, we found that our efficacy and 
SVR12 rates closely correlate with the ION studies; 
however, there appears to be an underlying renal risk 
associated with LDV/SOF regimens that was not seen 
during the initial ION trials, especially in those with pre-
existing CKD stage III or worse, and is only now being 
demonstrated in less controlled, retrospective analyses. 
The large exclusion criteria of the ION trials may sug-
gest why this renal risk is only now being unmasked in 
a less controlled, but more clinical, setting. We hypoth-
esize that our patient population demographics was a 
significant contributor to the higher incidence of AKI. 
When compared with the original ION trials, our pop-
ulation was both older (60 years old compared with 52) 
and had a larger percentage of African Americans (45% 
compared with 19%).(8,9)
Given these findings, there is a concern for potential 
renal complications associated with LDV/SOF-based 
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chronic HCV treatment. We do acknowledge that our 
sample size is limited and no definitive conclusions can 
be made regarding the role LDV/SOF plays in these 
transient eGFR decreases; furthermore, real-world 
data are required to accurately assess the safety profile 
of LDV/SOF.
Conclusions
In the treatment of chronic HCV infection, this 
large, single-center study observed AKI in 19% of our 
patients during treatment with LDV/SOF. Although 
renal impairment was seen nearly one-fifth of the 
time, most (61%) of those patients had transient 
improvement in renal function before completion of 
therapy. A significant greater incidence of AKI rates 
was identified for those with CKD III or worse com-
pared with those with CKD II or better, although 
the presence of cirrhosis or not was not significant in 
the development of AKI. Although close renal mon-
itoring is necessary, LDV/SOF treatment for chronic 
HCV infection overall appears to be safe. We suggest 
that prescribers closely monitor renal function and 
remain vigilant of renal impairment throughout treat-
ment duration, especially for those with baseline renal 
impairment.
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